Posted by Michael Wonder on 02 Sep 2020
NICE terminates yet another assessment of a new cancer medicine
2 September 2020 - This time it is a new medicine for patients with acute myeloid leukaemia.
NICE is unable to make a recommendation about the use in the NHS of glasdegib acetate for use in combination with chemotherapy for the treatment of newly diagnosed patients with acute myeloid leukaemia because Pfizer did not provide an evidence submission.
We will review this decision if Pfizer decides to make a submission.
